The study, published Oct. 23 in Circulation, looked at more than 7,500 patients with acute coronary syndrome who were treated with percutaneous coronary intervention.
They found stopping aspirin intake three months post-procedure did not increase risk of clotting or cardiac complications and significantly reduced the risk of severe bleeding, a possible aspirin side effect, by nearly 50%.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
